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Abortion is legally restricted in most of Latin America where 95% of the 4.4 million abortions performed annually
are unsafe.
Medical abortion (MA) refers to the use of a drug or a combination of drugs to terminate pregnancy. Mifepristone
followed by misoprostol is the most effective and recommended regime. In settings where mifepristone is not
available, misoprostol alone is used.
Medical abortion has radically changed abortion practices worldwide, and particularly in legally restricted contexts.
In Latin America women have been using misoprostol for self-induced home abortions for over two decades.
This article summarizes the findings of a literature review on women’s experiences with medical abortion in Latin
American countries where voluntary abortion is illegal.
Women’s personal experiences with medical abortion are diverse and vary according to context, age, reproductive
history, social and educational level, knowledge about medical abortion, and the physical, emotional, and social
circumstances linked to the pregnancy. But most importantly, experiences are determined by whether or not
women have the chance to access: 1) a medically supervised abortion in a clandestine clinic or 2) complete
and accurate information on medical abortion. Other key factors are access to economic resources and
emotional support.
Women value the safety and effectiveness of MA as well as the privacy that it allows and the possibility of having
their partner, a friend or a person of their choice nearby during the process. Women perceive MA as less painful,
easier, safer, more practical, less expensive, more natural and less traumatic than other abortion methods. The fact
that it is self-induced and that it avoids surgery are also pointed out as advantages. Main disadvantages identified
by women are that MA is painful and takes time to complete. Other negatively evaluated aspects have to do with
side effects, prolonged bleeding, the possibility that it might not be effective, and the fact that some women
eventually need to seek medical care at a hospital where they might be sanctioned for having an abortion and
even reported to the police.
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El aborto está legalmente restringido en la mayoría de América Latina donde 95% de los 4.4 millones de abortos
que se realizan anualmente son inseguros.
El aborto con medicamentos es el uso de una droga o una combinación de drogas para interrumpi el embarazo.
Mifepristona seguida de misoprostol constituye el regimen más efectivo y recomendado. En los lugares donde no
está disponible la mifepristona, se utiiza misoprostol solo.
El aborto con medicamentos ha transformado radicalmente la práctica del aborto a nivel mundial, y
particularmente en los contextos legalmente restrictivos. En América Latina, desde hace más de dos décadas, las
mujeres utilizan el misoprostol para autoinducirse abortos.
Este artículo resume los hallazgos de una revisión bibliográfica sobre las experiencias de las mujeres con el aborto
con medicamentos en países latinoamericanos donde el aborto voluntario es ilegal.
Las experiencias personales de las mujeres con el aborto con medicamentos son diversas y varían según el
contexto, la edad, la historia reproductiva, el nivel socioeconómico y el conocimiento acerca del aborto con
medicamentos así como las circunstancias físicas, emocionales y sociales que rodean a embarazo. Pero
fundamentalmente, las experiencias están determinadas por la posibilidad de las mujeres de acceder a: 1) un
aborto clandestino realizado bajo supervisión médica, o 2) información completa y precisa acerca del aborto con
medicamentos. Otros factores clave incluyen el acceso a recursos económicos y el apoyo emocional.
Las mujeres valoran la seguridad y efectividad del aborto con medicamentos así como la privacidad que ofrece y la
posibilidad de tener cerca a su pareja, un/a amiga/o, o persona de su confianza durante el proceso. Las mujeres
perciben al aborto con medicamentos como menos doloroso, más fácil, más seguro, más práctico, menos costoso,
más natural y menos traumático que otros métodos abortivos. Que sea auto-inducido y que evite el procedimiento
quirúrgico también son señalados como ventajas. Las principales desventajas identificadas son que es doloroso y
que lleva tiempo para que se complete. Otros aspectos evaluados negativamente incluyen los efectos secundarios,
el sangrado prolongado, la posibilidad de que no sea efectivo, y el hecho de que algunas mujeres eventualmente
deban solicitar atención médica en una institución donde sean sancionadas por haberse practicado un aborto y
hasta denunciadas a la policía.Background
Only 28% of countries –most of them in the developed
world– permit abortion upon request.a Unsafe abortion
and related mortality are both highest in countries with
narrow grounds for legal abortion. An estimated 21.6
million unsafe abortions took place worldwide in 2008,
almost all in developing countries, resulting in 47,000
maternal deaths and millions of women suffering injury,
illness and lifelong disability [1].
In Latin America, 95% of the 4.4 million abortions
performed annually are unsafe. Only Cuba, Mexico City,
Uruguay and several Caribbean islands have liberal abor-
tion laws [2]. The World Health Organization (WHO)
estimates that in 2008, 12% of all maternal deaths in the
region (1,100 in total) were due to unsafe abortion and
about one million women were hospitalized for treat-
ment of complications from unsafe abortion [1,2].
Despite legal restrictions, abortion is widely per-
formed. When faced with an unwanted pregnancy many
women will seek an abortion regardless of its legality.
The safety of a clandestine procedure depends on the
conditions under which it is performed which are pri-
marily determined by the woman’s socioeconomic status.
Women living in vulnerable social conditions who can-
not afford safe clandestine abortions often turn to riskymethods like the insertion of foreign bodies into the
uterus, drinking toxic solutions, or procedures per-
formed by unskilled providers [3,4]. Social and cultural
beliefs against abortion as well as stigma are other bar-
riers to safe abortion that make women turn to unsafe
methods [5]. In addition, fear of ill treatment and legal
reprisals might prevent women from seeking prompt
medical care after an abortion [1,6].
Medical abortion (MA) refers to the use of a drug or a
combination of drugs to terminate pregnancy. Mifepris-
tone followed by misoprostol is the most effective and
recommended regime. In settings where mifepristone is
not available, misoprostol alone is used.b Mifepristone is
an anti-progestin that blocks the action of progesterone,
a hormone necessary to maintain a pregnancy, and alters
the endometrium causing the uterine lining to shed.
Misoprostol is an analog of prostaglandin E1 that causes
the cervix to soften and the uterus to contract, resulting
in the expulsion of the uterine contents [7]. Until 63 days
of gestation WHO recommends 200 mg of miefepris-
tone administered orally followed by 800 mcg of miso-
prostol administered vaginally, buccally or sublingually
24 to 48 hours following ingestion of mifepristone [8]. In
the case of misoprostol alone, WHO recommends 800
mcg of misoprostol administered by vaginal or
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at least three hours [8].
Fist trimester medical abortion is a highly safe and ef-
fective procedure [8]. Up to 9 weeks gestation effective-
ness is 98% for the combined regime and between 75%
and 90% for misoprostol alone [7-9].
The effects of medical abortion are similar to those
associated with spontaneous abortion and include uter-
ine cramping and prolonged bleeding. Common side
effects include nausea, vomiting and diarrhea [7-9]. In
2005, the World Health Organization added mifepris-
tone and misoprostol to its List of Essential Medicinesc
for countries where abortion is not against the law. In
2009 misoprostol was also included for the treatment of
incomplete abortion.
Medical abortion has radically changed abortion prac-
tices worldwide, and particularly in legally restricted
contexts. Women can now access a non-invasive, safe
and effective method, which is more affordable than sur-
gical methods and does not require third party participa-
tion in the procedure [9,10]. In Latin America women
have been using misoprostol for self-induced home abor-
tions for over two decades [11]. As misoprostol became
more widely used the use of highly unsafe and invasive
abortion methods gradually became less frequent
[2,12,13].
While mifepristone is unlikely to be available in coun-
tries with restrictive abortion laws, misoprostol is avail-
able in most of Latin America. It is generally approved
to prevent gastric ulcers and not for gynecological and
obstetric indications, except for four countries in the
regiond which have it registered for some obstetric indi-
cation [14,15]. It is usually available in 200 mcg oral
tablets and in some countries it is associated with an
anti-inflammatory. It has been available in pharmacies
since the late 1980se [16].
Information about medical abortion spreads mostly by
word of mouth and through the Internet [17-19]. Phar-
macies usually dispense misoprostol despite the fact that
regulations in most countries require that it be sold only
under prescription [20-23]. Medical abortion drugs are
also accessed through providers in informal settings or
on the Internet [19,24,25]. Local and international
women’s groups and NGOs also disseminate information
on medical abortion through the Internet, printed mate-
rials and hotlines that provide instructions on how to
self-perform a medical abortion [19]. “Women on web”,
an international digital community, provides on-line
medical abortion services in different languages to
women living in countries where there are no safe
abortion services. Women complete a medical consult-
ation through an interactive web-based questionnaire
and if there are no contraindications they are sent a MA
kit (mifepristone +misoprostol) by postal mail.f InArgentina, Chile, Peru, Ecuador, Venezuela and Mexico
there are abortion hotlines that provide information on
how to use misoprostol for early pregnancy termination
based on scientific information published by the World
Health Organization and the Latin American Federation
of OBGyN Societies (FLASOG).
Some NGOs in legally restrictive settings have clinics
that provide information, counseling, medication and
health care services at low cost or no cost to women
seeking abortions. Some of these organizations offer
both medical and surgical abortions performed by physi-
cians, while others are run by trained non-medical coun-
selors who provide information as well as the
medication for the woman to administer herself, and fol-
low up services [17,18,20,26].
In several Latin American countries medical abortion
has enabled the implementation of harm reduction pol-
icies. Based on the right to health, autonomy, confidenti-
ality and information, health professionals provide
women with unwanted pregnancies pre-abortion coun-
seling including information on how to self-induce a
medical abortion, and postabortion care. Medication is
not provided since it would be against the law, women
have to obtain it by their own means. This strategy
proved highly effective to prevent abortion related ma-
ternal deaths [27].
There is evidence that shows that in countries where
voluntary abortion is not legal, increased use of med-
ical abortion over other methods has increased the
safety of self-induced procedures by reducing complica-
tions related to unsafe abortion [12,13,28-32]. Miso-
prostol and mifepristone are valuable resources that
have great potential to expand access to safe abortion
and therefore reduce maternal morbidity and mortality.
However, the efficacy and safety of MA in legally
restricted settings depends strongly on its adequate use
in terms of dosage and gestational age, and the avail-
ability and accessibility of quality postabortion care ser-
vices [12,13].
Globally, most research on medical abortion is situated
in legal abortion contexts and focuses on trials of medi-
cation regimes and cost-effectiveness analyses of medical
vs surgical abortion. Less attention has been paid to
women’s experiences, perspectives and preferences [33].
Given the importance of medical abortion in reshaping
the nature of abortion in legally restrictive settings, it is
crucial to have a deep understanding of women’s experi-
ences with this method.
This article summarizes the findings of a literature re-
view on women’s experiences with medical abortion in
Latin American countries where voluntary abortion is il-
legal. It includes studies focused on women’s perceptions
regarding knowledge, access and use of medical abortion
as well as the physical and subjective experience of
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has a dual aim: to consolidate available evidence about
the experiences of women who have a MA, and to foster
the political and academic debate around unsafe abor-
tion in Latin America and the key role that MA has in
making abortion safer.
Methodology
The review focused on studies produced in Latin America
since 1990 to June 2011. Evidence in Spanish, Portuguese
and English was identified through two different methodolo-
gies: 1) automatic searches of data bases (Lilacs,g Medline,h
Pubmed Central,i Poplinej and Cochranek). 2) Gray literature
search for unpublished or non-peer-reviewed sources by
contacting key institutions that conduct research on abortion
issues in the region, reviewing congresses abstracts, meeting
summaries and news bulletins from pertinent networks.l
Keywords used include: abortifacient agents; misoprostol;
methotrexate; mifepristone; abortion (abortion applicants;
induced abortion; voluntary abortion; therapeutic abortion);
interviews; stressful events; experiences; perception and
opinion, connected by Boolean operators available in the dif-
ferent data bases. Additional file 1: Table S1 which can be
accessed at http://cedes.org.ar/Rmw_oms_cedes_Table1.pdf
includes details of keywords used, search strategies by data
base and number of articles identified. Figure 1 shows the
process of applying the selection criteria to the items identi-
fied in the search.
Results
The literature review identified 27 articles/papers which are
highly diverse in terms of methodological approaches, data
collection techniques, design, inclusion criteria, and sample
methods.m Most studies were carried out between 2005
and 2011. Earlier production is scarce, except for the caseFigure 1 Summary of the findings of database search.of Brazil where over half a dozen articles were published in
the early and mid 1990s. Brazil was the first country to
report the use of misoprostol for self-induced clandestine
abortions, and most research addresses women hospitalized
for postabortion care [12,34-38].
Few studies focus exclusively on medical abortion,
while the rest address medical abortion within a wide
variety of issues related to the abortion event such as
reasons for seeking an abortion, the decision making
process, or attitudes towards abortion and include
women who used medical abortion as well as women
who resorted to other means of pregnancy termination.
In these cases, we only selected the information which
could shed light on the experience of undergoing a med-
ical abortion.
Studies differ in the time elapsed between the abortion
and the moment data was collected. Some only included
women who had had an abortion in the previous six
months or in the previous two years, while others en-
compass much longer periods of time, up to 20 years.
Selected studies can be classified in the following cat-
egories according to the study population and sample
used as shown on Additional file 2: Table S2.
Studies include both qualitative and quantitative
approaches that applied different data collection techni-
ques: 1) in-depth interviews focused on the narrative of
the abortion experience; 2) review of medical records
and surveys of women hospitalized for postabortion care
to describe socio-demographic characteristics, previous
use of contraception, abortion method used and inci-
dence of complications (these studies do not analyze in
depth the experience around self-inducing the abortion);
and 3) literature reviews.
Despite the diverse approaches, all articles address
critical aspects of the medical abortion experience. The
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present in the evidence reviewed which include: know-
ledge and information about medical abortion; choice
of method; obtaining the medication; the medical
abortion process: the physical and the psychological
experience.Knowledge and information about medical abortion
Women usually learn about MA when they have an un-
intended pregnancy. Previous knowledge is scarce and
superficial, often limited to knowing about the existence
of “abortion pills” that sometimes are confused with
emergency contraception [17,30,39-41].
Deciding to have an abortion and doing so is not a lin-
ear process, particularly in legally restricted settings, not
only because women might face ambivalence and per-
sonal, familial and social conflict, but also because they
might take several different “small actions” which do not
follow a sequential or organized pattern [42]. Faced with
an unwanted pregnancy, women start searching for solu-
tions that might eventually lead to a MA. Many find out
about MA only after unsuccessfully trying other sup-
posedly abortifacient methods such as herbal infusions
and hormonal injectables [17,18,25,26,30,39,43].
Clandestinity implies that information about MA is
not openly and publicly available but that it rather
flows through hidden informal or “underground” chan-
nels. Female relatives, friends, neighbors and the sexual
partner, are the ones who provide information or help to
identify sources of information such as women who
had abortions in the past or who have been close to
women in a similar situation, women’s health organiza-
tions, health professionals, pharmacies and Internet sites
[11,24,35,36,39,43,44].
Women who reach harm reduction services often find
out about MA through the counseling provided [25]. In
some cases men lead the search for information resort-
ing to other men who can provide advice [12,45,46]
while women adopt a more passive stance [47].
Information about MA is mostly spread by word of
mouth and it is therefore highly diverse and fragmented,
particularly when it comes from laypeople, but pharmacy
staff and health professionals also provide highly hetero-
geneous information that in some cases differs signifi-
cantly from scientific standards [19-21,23,30,39,44,48].
Complete and correct information about how to
use and what to expect from MA, including dosage,
routes of administration, mechanism of action, effective-
ness, contraindications and side effects is crucial in
determining the outcome of the process and the
woman’s experience. Women who receive accurate and
complete information on how the medical abortion
process will develop and what is and what is not normalhave more positive experiences. In this sense, counseling
by a health care professional or a qualified counselor is
vital for the whole abortion process [4,13,25,39].
Choice of method
As with most abortion matters within legally restricted
settings, the experience of undergoing a medical abor-
tion is primarily determined by social class. Lower in-
come women do not have an array of safe methods to
choose from according to their needs and preferences
[39,49], but they do perceive that using medication is
safer than introducing objects or other traditional unsafe
methods [12,24]. Preference for MA is also expressed
based on fear of unsafe medical procedures or because
they associate it more with a menstrual regulation
process. However, cost and accessibility are key factors
for deciding for a MA, more than personal preferences
or a balance of its advantages and disadvantages.
Women make pragmatic decisions regarding the
abortion method based on their possibilities that are
not necessarily “real choices” [17,18]. In the absence of
financial constraints some would prefer a surgical abor-
tion performed by a physician or a medically supervised
procedure [35,39,49].
Women value the safety and effectiveness of MA as
well as the privacy that it allows and the possibility of
having their partner, a friend or a person of their choice
nearby during the process. Women perceive MA as less
painful, easier, safer, more practical, less expensive, more
natural and less traumatic than other methods. The fact
that it is self-induced and that it avoids surgery is also
pointed out as an advantage [11,17,18,24,35,44].
Main disadvantages identified by women are that MA
is painful and takes time to complete. Other negatively
evaluated aspects have to do with side effects, prolonged
bleeding, the possibility that it might not be effective,
and the fact that some women eventually need to seek
medical care at a hospital where they might be sanc-
tioned for having an illegal abortion and even reported
to the police [11,17,18].
Obtaining the medication
In most cases women have to procure the medication by
themselves, except those who access MA through an in-
stitution or a health professional that provides misopros-
tol. Risk reduction services offer information on medical
abortion as a way to avoid higher risk methods but
women must obtain the drug on their own. Some
women feel highly frustrated when they learn that abor-
tions are not practised nor is misoprostol provided by
such services [25].
In many Latin American countries pharmacies are
widely used as a source of medical advice, especially by
lower income populations, and women have traditionally
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menstruation when they have a delayed menstrual
period [13,21]. Misoprostol is purchased at retail phar-
macies either as the entire package or by the pill,
usually without prescription despite the fact that
government regulations require sale under prescrip-
tion [11,20-22,34]. Pharmacy staff often recommend
misoprostol for pregnancy termination but their
knowledge about dosage, route of administration, side
effects complications and effectiveness is often poor
in quality [20,21]. They usually advise to seek medical
care once bleeding starts [22].
Different levels of difficulty exist in obtaining miso-
prostol related to the local regulation of the drug and
the level of government control over pharmacy sales.
Stricter control makes access more difficult, pushing
women to the black market where prices are higher
[25,48,50].
In settings where misoprostol is sold only under pre-
scription women display a variety of strategies to either
obtain a prescription or to buy the drug without one.
These include paying for a prescription, claiming that
the drug is not for ObGyn purposes either by obtaining
and presenting a prescription from a non-ObGyn spe-
cialist, or asking a man or an older woman to buy the
drug for them arguing that is for their own use [22].
Internet is extensively used to search for information
on MA and to a lesser extent to buy misoprostol. The
quality and authenticity of misoprostol sold on the Inter-
net by individuals with lucrative purposes is questionable
since it is sometimes not provided in its original pack-
aging and can be fake [19,50,51]. The studies reviewed
do not report use of telemedicine websites or hotlines
for obtaining MA medication among Latin American
women.n
Prices vary widely, and depend on where the medica-
tion is purchased [16,39,40]. Even if medical abortion is
considerably less expensive than surgical methods, it is
still unaffordable for poor women and adolescents who
do not have ready access to cash. Women implement
different strategies to gather the money to buy the medi-
cation: borrowing money from friends and relatives, ask-
ing for a salary advance, working overtime, selling
valuable objects [25,39,49]. One study even refers to
women travelling or contacting people in neighboring
countries to obtain the medication [39].
Sometimes women who bought the whole package
and have pills left after completing the abortion
either offer them or sell them to other women in need
of misoprostol as a way of female solidarity or cost-
recovery [22,39].
Obtaining the drug implies not just having the money
but entering the circuit of irregular sale of misoprostol.
Internet is the main source of this kind of information.Accessing the drug will depend on the woman’s eco-
nomic capacity, social network, personal skills, and support
from others. Male partners who are involved in the abor-
tion decision usually have an active role in obtaining the
medication, particularly in contributing economically and
searching for where to buy it [12,25,46].The medical abortion process: the physical experience
Like the majority of abortions, most medical abortions
take place within the first 12 weeks of pregnancy
[11,12,32,39,40]. Women generally understand that earl-
ier abortions are safer, but sometimes the abortion is
delayed because time is spent seeking information, trying
ineffective methods, searching for the medication and
raising the money to buy it [30,39]. Second and even
third trimester self-induced home abortions with miso-
prostol have been reported [11,34]. These situations can
be extremely risky.
For most women, getting ready for a medical abortion
means preparing for something unknown, an unexper-
ienced event that can trigger unexpected consequences
[39,49]. They must decide when and where to do it, if
someone will be with them at that moment and who
they want that person to be. If they have children they
must arrange for someone to look after them and
organize the domestic chores [17,18,39].
Women appreciate the privacy that medical abortion
allows them. In some circumstances they conceal the
abortion from other people. There are testimonies of
women who went through a MA without altering their
daily lives and surrounded by relatives, or even their
partner, who were unaware of their condition. In other
cases, hiding the abortion from other household mem-
bers is difficult and problematic [17,26,44].
Women often prefer to use the pills during the night as
they perceive it to be safer, with few chances of being inter-
rupted, and they are usually at home while others are rest-
ing [12,17,39]. The night might also feel like a more private
and protected time for doing something illegal [39].
It is not uncommon for women to use misoprostol to-
gether with other methods, mostly ineffective ones like
teas and other infusions, and injections bought in phar-
macies [12,51,52].
Few of the women who obtain the medication outside
clinical settings can specify the name of the medication
they used for pregnancy termination [17,39,40,44,49,53]
and cannot precise if they were antibiotics, analgesics or
tranquilizers [17].
The information that women receive outside clinical
settings about how to use misoprostol is highly di-
verse, consequently, women use misoprostol in a var-
iety of ways [24,35,51] with doses ranging between 4
and 16 tablets, and much higher doses in extreme
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ally 800 mcg, the adequate dosage for early abortion
[34,35,37]. Intervals between doses also vary widely
[24].
Women use misoprostol vaginally, orally or a combin-
ation of both routes [24,35-37] and seem to prefer oral
rather than vaginal administration [13]. Some women
dislike or are uncomfortable with the vaginal administra-
tion of tablets, or are not sure they can insert them
correctly by themselves. Several authors relate oral
preference to the idea of menstrual regulation, while
vaginal insertion is culturally more linked to abortion
[12,17].
After inserting or taking the pills women wait for
something to happen. When possible, they stay home
and rest. Others continue with their daily routines. In
some cases expulsion or heavy bleeding took them by
surprise while they were at school or at work [17,49].
Bleeding usually starts few hours after the first dose
and is most abundant at 6 to 12 hours after insertion
[44] but can also take much longer [24,35]. Bleeding can
last between 1 and 60 days [24]. Several studies report
testimonies of heavy bleeding, or bleeding more abun-
dant than what women had expected [30,40]. Often
women are unable to determine whether their symptoms
are normal or abnormal or whether a complete abortion
has occurred [30].
Common side effects include chills, diarrhea, nausea,
headache, dizziness and fever. These are usually well tol-
erated [17,40]. Most women experience pain of different
intensity and duration [24,40,44]. Generally the most se-
vere pain takes place the first day after inserting/taking
the pills, particularly after 5 to 7 hours, and later
diminishes [44]. Some women report unbearable sus-
tained pain for several hours [17,25,26]. Those who have
medical supervision are recommended to take pain relief
medication [17].
Some women start and finish the MA process at
home. Others do not wait enough to complete the abor-
tion alone and seek medical assistance in health care
institutions where a surgical uterine evacuation proced-
ure is usually performed. Some women seek medical
care shortly after bleeding starts, either because they are
afraid that something bad will happen to them, or be-
cause they were told to do so by the person who
instructed them on how to use the medication
[12,20,22,30,35,36,44,45].
As information on MA becomes more widespread and
women gain more experience they make better use of
misoprostol [11,35]. Evidence collected from hospitalized
postabortion women shows that prevalence of severe
complications is lower among women who used miso-
prostol than among those who used other methods
[29,34,35].In some cases attempts to terminate pregnancy with
misoprostol are not successful and pregnancy continues.
Women who access medical services that perform abor-
tions can resort to a surgical abortion [17,18,26]. But
women who lack this alternative are left with no options.
The possibility of having a surgical procedure depends
on their economic capacity. These are critical situations
marked by anxiety and distress, particularly when
women are aware of the possible teratogenic effects of
the medication [39].The psychological experience
Having a medical abortion means a direct and vivid
physical experience which triggers strong emotions, fan-
tasies and fears. Few of the articles reviewed refer to the
psychological aspects of the MA experience, which are
closely related to the physical experience, the informa-
tion the woman has received, and the availability or lack
of medical and emotional support [17,18,39,45,49].
Some women relate MA to a menstrual regulation
process or something akin to getting their period, which
reduces emotional distress and helps them to cope with
the process [11,17,18,44]. On the other hand, many
women go through a MA feeling that it is an unknown
process of which they have no full control [39]. Com-
mon feelings are fear of the negative reactions in the
body, and concern linked to pain and bleeding. Women
are very anxious about heavy vaginal bleeding and fear
they can bleed to death or suffer long lasting health
complications including infertility [25,43,51]. Women
who have legal medical abortions in a medically con-
trolled setting are less concerned about bleeding [56].
Testimonies also reflect uncertainty and anxiety about
how long the process will last, when they will be able to
return to their daily life and whether or not certain ac-
tivities are safe to do (working, swimming, bathing,
physical activity, sex) [17].
Women who have medical supervision and/or receive
detailed information from a qualified source and know
what to expect in terms of bleeding, pain and side effects
report more positive experiences with less anxiety and
fear, feel more in control and tend to remain calm [29].
In addition, previous experience with pregnancy and de-
livery seems to contribute to a better management of the
situation [17].
Many women, but particularly those who undergo the
process with no counseling or supervision, have emo-
tionally draining experiences marked by fear of negative
consequences, anxiety and concern. These are mostly
elicited by the clandestine context and the lack of med-
ical back-up in moments when women feel extremely
vulnerable and out of control of the situation [39,45].
Some women refrain from seeking medical care out of
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medication to retain the pregnancy [43].
Affective support and company are vital during the
MA process, particularly for adolescents who are more
vulnerable than older women in the same situation
[25,26]. Women are usually accompanied by their part-
ner, female relatives (mother, sister) or female friends
who help to minimize discomfort or simply stay by them
[17,25,39,49]. Having the support of their close ones
gives women not only the possibility of sharing doubts
and fears, and not feeling alone -which is reassuring and
helps them to remain calm- but also implies the possibil-
ity of accessing economic resources or having someone
who will take care of their children if they have any
[25,39]. Women who go through the process alone or
conceal the abortion from other household members
usually have emotionally difficult situations [17,25,47].
Conclusions
Women’s personal experiences with medical abortion
are diverse and vary according to context, age, repro-
ductive history, social and educational level, knowledge
about medical abortion, and the physical, emotional, and
social circumstances linked to the pregnancy. But most
importantly, experiences are determined by whether or
not women have the chance to access: 1) a medically
supervised abortion in a clandestine clinic, or 2)
complete and accurate information on medical abortion.
Other key factors are access to economic resources and
emotional support.
The experiences of women who access medical abor-
tion under clinical supervision or who receive qualified
counseling vary significantly from those who use miso-
prostol on their own or with the help of laypeople.
Women who access MA services provided by trained
personnel have the most positive experiences. They are
assured genuine medication, have medical backup in
case of complications and can resort to a surgical pro-
cedure in case of medical abortion failure or incomplete
abortion. Women who do not access this type of services
are on their own during the whole process, including
finding alternative solutions if the attempts with miso-
prostol are not successful. Their experiences are charac-
terized by anxiety and fear of negative consequences to
their health. Doing something illegal and acting in a
clandestine way is a major cause of distress that makes
women feel vulnerable and unprotected. The presence of
significant others and social networks are helpful during
the whole process.
Overall women find MA acceptable even though it
might not be their first choice if they had the possibility
to select between surgical or medical methods. The posi-
tive and negative attributes of MA perceived by women
in legally restricted contexts are very similar to thoseexpressed by women in legal abortion settings [33,57-59]
The major difference lies in the confidence that legal-
ity provides and the reassurance that the heath system
accompanies them and cares for them during the abor-
tion process.
Women who have MAs in legally restricted settings
access mostly misoprostol and they tend to use it in ra-
ther adequate doses. The literature reviewed over a
20 year period shows that recent studies report more
proper use of misoprostol while older studies refer to
more “anarchic use” including excessive doses. Also,
most side effects described are similar to those reported
in clinical trials [8]. This could be indicating that
information on MA is becoming more widespread in
the region.
The information on the psychological experience of
women who have medical abortions in legally restricted
settings does not allow to make comparisons with
the abortion experience in general. However, using a
self-induced method in the privacy of their homes
seems to reduce the stress related to the illegal character
of abortion.
Latin America has a long tradition of academic pro-
duction and social research in sexual and reproductive
health and a strong women’s movement mobilized
around the abortion issue [60,61]. However, the litera-
ture review shows that there are few studies in the re-
gion that specifically focus on the medical abortion
experience from the woman’s perspective. Furthermore,
several countries have no research production on this
field at all. Research on abortion in legally restricted
settings implies additional ethical and logistical
obstacles to a naturally socially sensitive issue
which affect the possibility of exploring the issue and
obtaining valid information, particularly when it
involves approaching women who have had illegal
abortions [61,62].
The evidence reviewed is highly heterogeneous and
was produced by different approaches and methodolo-
gies; therefore a comparative analysis is not possible.
Most available research is based on samples of women
hospitalized after an abortion or women who accessed
risk reduction services. Only a minority of studies in-
clude women who completed the MA process alone,
without preabortion counseling and/or postabortion
care. Adolescent women are underrepresented in the
available studies and the experience of those under age
15 is completely absent. We know nothing about women
who had failed medical abortions and continued on with
their pregnancy, and very little about those who had a
legal abortion within the health care system or those
who received misoprostol for postabortion care. In
addition, most literature comes from large urban set-
tings, and few studies include rural or indigenous
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medical abortion in Latin American is needed in order
for researchers, activists, policy makers and health care
providers to have a better and more comprehensive
understanding of its impact on women’s lives and health.
Given the results of this literature review, it is clear
that the research agenda on women’s experiences with
medical abortion is not yet fully developed in the Latin
American region. More research is needed in order to
get a comprehensive picture. Different subpopulations
and issues need to be addressed and other study designs
and methodologies implemented. The experience with
medical abortion and its results and impact on adoles-
cents, rural and indigenous women, and women acces-
sing legal abortions within restrictive legal contexts need
to be better understood. Issues such as the experience of
successful use of medical abortion by women who use it
with no medical supervision needs to be better assessed
given the potential of medical abortion as a self-used
technology. As for study designs, general population is
still not in the picture and it should be. In order to over-
come the limitations of the widely used convenience
sampling methods, respondent-driven sampling (RDS)
needs to be assessed as a probabilistic sampling strategy
to study this specific hard-to-reach population [63].
Additionally, comparative analysis among countries
needs also to be developed not only to understand the
use of this new technology in different cultural and so-
cial contexts but also to get a more robust understand-
ing of its impact on women’s experiences in legally and
culturally restrictive environments.
Women in developing countries where abortion is le-
gally restricted have a great need for safe, affordable and
simple abortion methods. Misoprostol is a very import-
ant contribution which has facilitated women better ac-
cess than ever before to an effective and safe method for
early self-induced pregnancy termination. This has had a
positive impact on their health. Women need to have ac-
cess to detailed and complete information on MA
through a wide array of communication channels, as
well as pre and post abortion services to optimize the
great potential that MA has to make abortions safer in
legally restrictive settings.
Endnotes
a98% of countries in the world allow abortion to save a
woman’s life, most of them also permit one or several fur-
ther conditions. However, in many settings legal abortions
are hard to access and are rarely officially practiced [1].
bMethotrexate has also been used in combination with
misoprostol as a medical method for early abortion in some
countries where mifepristone is not available. However, a
WHO toxicology panel recommended against the use of
methotrexate for inducing abortion, based on concerns ofteratogenicity if the method fails and the pregnancy is not
interrupted [8].
cThe WHO List of Essential Medicines contains those
medicines which are considered to satisfy the priority
health needs of the population of developing countries,
and which have been selected on the basis of their effi-
cacy, safety and cost-effectiveness.
dBrazil, Peru, Mexico [14] and Argentina [15].
eIn the case of Brazil, in the late eighties misoprostol
was available over the counter in pharmacies and be-
came a popular abortifacient method. In 1991 the gov-
ernment severely restricted its sale and in some states it
was completely banned. Currently it is sold exclusively
for hospital use. However, misoprostol continues to be
sold in the black market [16,34].
fIn 2008 Gomperts et al. published a study based on
484 women from 33 different countries who contacted
Women on Web and received a medical abortion kit
(mifepristone +misprostol) by postal mail. Results show
that women seem capable of self-administering MA
when proper information and instructions are provided
through Internet and additional interactive online con-
sultations and email correspondence [64].
gLatin American and Caribbean Health Sciences
Information.
hU.S. National Library of Medicine.
iU.S. National Institutes of Health.
jJohn's Hopkins Bloomberg School of Public Health.
kThe Cochrane Collaboration.
lIn 2009, the Latin American Consortium against Un-
safe Abortion (CLACAI) carried out a literature review
on Latin American women’s experiences with medical
abortion coordinated by Nina Zamberlin which included
designing a methodology for data collection [65]. In
2010 CLACAI created RepoCLACAI, a repository on
abortion that systematizes research studies, technical
documents and guidelines produced in the Latin Ameri-
can region (www.clacaidigital.info).
mStudies were not quality assessed and therefore none
was excluded on such basis.
nGomperts et al. analyze access and use to MA through
Women on Web (www.womenonweb.org) by women in 33
different countries where abortion is legally restricted, but
data is not disaggregated by country or region [64].Additional files
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